Autologous hematopoietic stem cell transplantation for patients with diffuse large B-cell lymphoma: a retrospective study.
10.7534/j.issn.1009-2137.2013.03.016
- Author:
Xiao-Lin LU
1
;
Yan LI
;
Wen-Rong HUANG
;
Yue-Lu GUO
;
Xiao-Li ZHAO
;
Ning LU
;
Hai-Yan ZHU
;
Quan-Shun WANG
;
Li YU
;
Yu JING
Author Information
1. Department of Hematology, Chinese PLA General Hospital, Beijing, China.
- Publication Type:Journal Article
- MeSH:
Adolescent;
Adult;
Child;
Female;
Hematopoietic Stem Cell Transplantation;
Humans;
Lymphoma, Large B-Cell, Diffuse;
mortality;
therapy;
Male;
Middle Aged;
Prognosis;
Retrospective Studies;
Survival Rate;
Transplantation, Autologous;
Treatment Outcome;
Young Adult
- From:
Journal of Experimental Hematology
2013;21(3):617-622
- CountryChina
- Language:Chinese
-
Abstract:
The purpose of this study was to investigate the efficacy of autologous hematopoietic stem cell transplantation (auto-HSCT) for patients with diffuse large B-cell lymphoma (DLBCL), and analyse the factors influencing prognosis. The clinical data of 67 patients with DLBCL received auto-HSCT from 1996 to 2011 and cumulative overall survival (OS), progression-free survival (PFS), transplant-related mortality (TRM), and relapse rate were retrospectively analyzed. The results showed that the median follow-up time was 40 months after transplantation. Three-year cumulative OS and PFS were 70.6% and 66.4% respectively, 5-year cumulative OS and PFS were 70.6% and 63.8% respectively, and TRM was 7.2%. One-year and three-year cumulative relapse rate were 16.5% and 23.7% respectively. Univariate analysis revealed that the age and pre-transplant disease status were significantly associated with poor prognosis (P < 0.05). It is concluded that auto-HSCT is a safe and effective therapeutic option for patients with DLBCL, especially for the young patients or patients with better remission.
